Stock Ticker

  • Loading stock data...

Merck & Co., Inc. (NYSE:MRK) Achieves Limited Success Of Steglatro In Reducing The Risk Of Patients With Total Hospitalizations

Merck & Co., Inc.  (NYSE:MRK) reported only limited success in lowering patients’ total hospitalizations with heart failures.

According to recent clinical data, Merck’s Steglatro could overall reduce cardiovascular death or total hospitalization risks by just 17% or lower the risk of the patient by 30%. In a statement, Merck said the first hospitalizations rate remains the same irrespective of whether they suffered heart failure earlier.

SGLT2 meds are effective on cardiovascular outcomes

Associate Vice President (clinical research for diabetes and endocrinology) of Merck, Dr. Sam Engel, said the recent findings show the effectiveness of SGLT2 medications on patients’ cardiovascular outcomes. He further said a further study is needed to verify the consistency of the benefits.

Gefapixant reduces cough frequency

Merck conducted a Phase 3 clinical trial of orally administered and selective P2X3 receptor antagonist – MK-7264 to evaluate the safety and efficacy in treating chronic cough.

The company administered 45 mg of Gefapixant (MK-7264) orally daily twice in adult patients with chronic cough. They have shown significant progress in reducing cough frequency over 24 hours compared to placebo in a 12-week clinical study. However, a dosage of 15 mg twice daily failed to achieve the primary endpoint.

Clinical Professor Dr. Lorcan McGarvey said 5 to 10% of adults worldwide suffer from a chronic cough. A percentage of these patient populations suffer from unexplained or refractory chronic cough and sensitive to various triggers that may not cause cough in healthy patients. MK-7264 showed a promising outcome to address this unmet need.

The positive outcome of the V114 clinical trial

Merck achieved a positive outcome from the Phase 3 clinical study of V114. The company evaluates this drug to find out the immunogenicity, tolerability, and safety in adults aged 50 years or older. This 15-valent pneumococcal conjugate vaccine is on par with PCV13 (13-valent pneumococcal conjugate vaccine), currently available in the market. The PNEU-AGE achieved the secondary endpoint also. In both the clinical studies involving V114-019 and V114-020, the patients tolerated the drug, and the safety profile is also excellent.

Merck engages in the discovery/ development of innovative vaccines and medicines to treat infectious diseases.

Recent Stories

SignUp Now For Our Featured Newsletter